Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation

Dutch Uro-Oncology Studygroup

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)


BACKGROUND: Abiraterone Acetate (AA) and Enzalutamide (Enz) are effective hormonal treatments in mCRPC patients. Retrospective studies suggested clinical cross-resistance between Enz and AA. However, 12.8-39.1% of patients previously treated with docetaxel (Doc) and AA do respond to Enz. These responders have not been characterized.

METHODS: 102 Enz treated mCRPC patients after AA and Doc treatment were included in this study. Differences in patient characteristics and previous treatment outcomes between PSA responders and non-responders on Enz were evaluated.

RESULTS: Median Progression-Free Survival was 12.2 weeks (95%CI 11.7-14.3) and Overall Survival 43.5 weeks (95%CI 37.4-61.2). There were 26 (25%) Enz-responders and 76 (75%) non-responders. Significant higher percentages of Gleason scores ≥ 8 and PSA doubling times (PSA-DT) <3 months were found in Enz responders than in non-responders. The interval between end of AA and start of Enz treatment (IAE) for responders was 24.6 weeks (IQR 4.0-48.1) and 8.9 weeks for non-responders (IQR 3.7-25.9) (P = 0.08). In an IAE <40 days subgroup (34 patients), Enz responses were related to AA non-responsiveness, while univariate and logistic regression analysis of baseline criteria of a subgroup of patients with an IAE ≥ 40 (68 patients) revealed significant differences in baseline PSA levels, PSA-DT <3 months, Gleason scores ≥ 8 and IAE's between Enz responders and non-responders.

CONCLUSIONS: PSA response to Enz after previous AA and Doc treatment was associated with a longer IAE, a higher Gleason score and a PSA-DT <3 months. Identification of these patients might be of value for sequencing of treatment options.

Original languageEnglish
Pages (from-to)32-40
Number of pages9
Issue number1
Publication statusPublished - Jan 2016


  • Aged
  • Androstenes
  • Antineoplastic Agents
  • Disease-Free Survival
  • Drug Monitoring
  • Drug Resistance, Neoplasm
  • Drug Substitution
  • Humans
  • Journal Article
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Netherlands
  • Phenylthiohydantoin
  • Prognosis
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant
  • Retrospective Studies
  • Taxoids
  • Treatment Outcome

Cite this